Extract
COVID19 led to an unprecedented number of patients on mechanical ventilation, many of them presenting with severe acute respiratory distress syndrome (ARDS) [1–4]. Depending on the resources of national health care systems, extracorporeal membrane oxygenation (ECMO) was frequently applied during the pandemic [3, 5–7]. While ICU experience improved with this new disease, various forms of drug therapies were introduced in living guidelines, resulting in a dynamic development in outcome of COVID19 [8, 9].
Footnotes
Conflict of interest: Christian Karagiannidis reported advisory fees for Xenios and lecture fees for Xenios and Getinge.
Conflict of interest: Thomas Bein has nothing to disclose.
Conflict of interest: Tobias Welte reported reported advisory fees for Xenios.
- Copyright ©The authors 2022. For reproduction rights and permissions contact permissions{at}ersnet.org
LIBRARY USERS
Log in through your institution
Purchase access
